Trial Profile

The influence of Telmisartan on insulin resistance and fatty liver in patients suffer from hypertension: A phase IV, randomised controlled trial.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 May 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telmisartan (Primary)
Indications Fatty liver; Hypertension; Insulin resistance
Focus Therapeutic Use
Acronyms InReTel

Most Recent Events

26 Apr 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
15 Mar 2012 Planned end date changed from 30 Sep 2011 to 11 Jun 2013 as reported by European Clinical Trials Database.
15 Mar 2012 Actual initiation date chnaged from 15 Feb 2010 to 11 Dec 2009 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com